CSL (OTCMKTS:CSLLY - Get Free Report) was upgraded by equities research analysts at The Goldman Sachs Group to a "strong-buy" rating in a research note issued to investors on Thursday,Zacks.com reports.
CSL Trading Up 0.4 %
Shares of CSLLY stock traded up $0.33 during trading hours on Thursday, hitting $86.16. 75,267 shares of the company's stock traded hands, compared to its average volume of 62,051. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.18 and a quick ratio of 0.97. CSL has a 12 month low of $83.31 and a 12 month high of $109.00. The stock's 50 day simple moving average is $89.07 and its 200 day simple moving average is $96.46.
CSL Company Profile
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Stories
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
